Vaccine development. On relating immunology to the Third World: Some studies on leprosy

B. R. Bloom, P. Salgame, V. Mehra, H. Kato, R. Modlin, T. Rea, P. Brennan, J. Convit, L. Lugozi, S. Snapper, W. Jacobs

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Leprosy is of interest to immunologists because the varied clinical manifestations of the disease correlate closely with the immunological spectrum. Resistance to infection is dependent on appropriate cell-mediated immunity, but patients with the lepromatous form fail to respond to antigen of M. leprae. In vitro studies have revealed the existence of T-suppressor cells of the phenotype CD8+, CD3+, HLA-DR+, FcR+, 9.3-, which are restricted by major histocompatibility complex (MHC) class II antigens. Several new candidate vaccines against leprosy have been effective in breaking immunological unresponsiveness and engendering cell-mediated immunity in lepromatous leprosy patients, including the combination of BCG + killed M. leprae. Because BCG has unique adjuvant properties, we have begun to use molecular genetic approaches to develop BCG into a multivaccine vehicle capable of immunizing simultaneously against several pathogens. Both phage-based and plasmid-based strategies have been developed for introducing selectable markers into BCG for the first time.

Original languageEnglish (US)
Pages (from-to)87-90
Number of pages4
JournalImmunology
Issue numberSUPPL. 2
StatePublished - Jan 1 1989

Fingerprint

Leprosy
Mycobacterium bovis
Allergy and Immunology
Vaccines
Cellular Immunity
Lepromatous Leprosy
Histocompatibility Antigens Class II
HLA-DR Antigens
Major Histocompatibility Complex
Bacteriophages
Molecular Biology
Plasmids
Phenotype
Antigens
Infection

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Bloom, B. R., Salgame, P., Mehra, V., Kato, H., Modlin, R., Rea, T., ... Jacobs, W. (1989). Vaccine development. On relating immunology to the Third World: Some studies on leprosy. Immunology, (SUPPL. 2), 87-90.

Vaccine development. On relating immunology to the Third World : Some studies on leprosy. / Bloom, B. R.; Salgame, P.; Mehra, V.; Kato, H.; Modlin, R.; Rea, T.; Brennan, P.; Convit, J.; Lugozi, L.; Snapper, S.; Jacobs, W.

In: Immunology, No. SUPPL. 2, 01.01.1989, p. 87-90.

Research output: Contribution to journalArticle

Bloom, BR, Salgame, P, Mehra, V, Kato, H, Modlin, R, Rea, T, Brennan, P, Convit, J, Lugozi, L, Snapper, S & Jacobs, W 1989, 'Vaccine development. On relating immunology to the Third World: Some studies on leprosy', Immunology, no. SUPPL. 2, pp. 87-90.
Bloom BR, Salgame P, Mehra V, Kato H, Modlin R, Rea T et al. Vaccine development. On relating immunology to the Third World: Some studies on leprosy. Immunology. 1989 Jan 1;(SUPPL. 2):87-90.
Bloom, B. R. ; Salgame, P. ; Mehra, V. ; Kato, H. ; Modlin, R. ; Rea, T. ; Brennan, P. ; Convit, J. ; Lugozi, L. ; Snapper, S. ; Jacobs, W. / Vaccine development. On relating immunology to the Third World : Some studies on leprosy. In: Immunology. 1989 ; No. SUPPL. 2. pp. 87-90.
@article{e5b4e838c0d64534a49ddd5bf10f893a,
title = "Vaccine development. On relating immunology to the Third World: Some studies on leprosy",
abstract = "Leprosy is of interest to immunologists because the varied clinical manifestations of the disease correlate closely with the immunological spectrum. Resistance to infection is dependent on appropriate cell-mediated immunity, but patients with the lepromatous form fail to respond to antigen of M. leprae. In vitro studies have revealed the existence of T-suppressor cells of the phenotype CD8+, CD3+, HLA-DR+, FcR+, 9.3-, which are restricted by major histocompatibility complex (MHC) class II antigens. Several new candidate vaccines against leprosy have been effective in breaking immunological unresponsiveness and engendering cell-mediated immunity in lepromatous leprosy patients, including the combination of BCG + killed M. leprae. Because BCG has unique adjuvant properties, we have begun to use molecular genetic approaches to develop BCG into a multivaccine vehicle capable of immunizing simultaneously against several pathogens. Both phage-based and plasmid-based strategies have been developed for introducing selectable markers into BCG for the first time.",
author = "Bloom, {B. R.} and P. Salgame and V. Mehra and H. Kato and R. Modlin and T. Rea and P. Brennan and J. Convit and L. Lugozi and S. Snapper and W. Jacobs",
year = "1989",
month = "1",
day = "1",
language = "English (US)",
pages = "87--90",
journal = "Immunology",
issn = "0019-2805",
publisher = "Wiley-Blackwell",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Vaccine development. On relating immunology to the Third World

T2 - Some studies on leprosy

AU - Bloom, B. R.

AU - Salgame, P.

AU - Mehra, V.

AU - Kato, H.

AU - Modlin, R.

AU - Rea, T.

AU - Brennan, P.

AU - Convit, J.

AU - Lugozi, L.

AU - Snapper, S.

AU - Jacobs, W.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Leprosy is of interest to immunologists because the varied clinical manifestations of the disease correlate closely with the immunological spectrum. Resistance to infection is dependent on appropriate cell-mediated immunity, but patients with the lepromatous form fail to respond to antigen of M. leprae. In vitro studies have revealed the existence of T-suppressor cells of the phenotype CD8+, CD3+, HLA-DR+, FcR+, 9.3-, which are restricted by major histocompatibility complex (MHC) class II antigens. Several new candidate vaccines against leprosy have been effective in breaking immunological unresponsiveness and engendering cell-mediated immunity in lepromatous leprosy patients, including the combination of BCG + killed M. leprae. Because BCG has unique adjuvant properties, we have begun to use molecular genetic approaches to develop BCG into a multivaccine vehicle capable of immunizing simultaneously against several pathogens. Both phage-based and plasmid-based strategies have been developed for introducing selectable markers into BCG for the first time.

AB - Leprosy is of interest to immunologists because the varied clinical manifestations of the disease correlate closely with the immunological spectrum. Resistance to infection is dependent on appropriate cell-mediated immunity, but patients with the lepromatous form fail to respond to antigen of M. leprae. In vitro studies have revealed the existence of T-suppressor cells of the phenotype CD8+, CD3+, HLA-DR+, FcR+, 9.3-, which are restricted by major histocompatibility complex (MHC) class II antigens. Several new candidate vaccines against leprosy have been effective in breaking immunological unresponsiveness and engendering cell-mediated immunity in lepromatous leprosy patients, including the combination of BCG + killed M. leprae. Because BCG has unique adjuvant properties, we have begun to use molecular genetic approaches to develop BCG into a multivaccine vehicle capable of immunizing simultaneously against several pathogens. Both phage-based and plasmid-based strategies have been developed for introducing selectable markers into BCG for the first time.

UR - http://www.scopus.com/inward/record.url?scp=0024465139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024465139&partnerID=8YFLogxK

M3 - Article

C2 - 2680926

AN - SCOPUS:0024465139

SP - 87

EP - 90

JO - Immunology

JF - Immunology

SN - 0019-2805

IS - SUPPL. 2

ER -